Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC
| العنوان: | Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC |
|---|---|
| المؤلفون: | Kurt Miller, Cora N. Sternberg, Amanda Bruno, Helen Guo, Daniel J. George, XiaoLong Jiao, Bertrand Tombal, Neal D. Shore, Neeraj Agarwal, Per Sandstrom, Celestia S. Higano, Oliver Sartor, Fred Saad, Frank Verholen |
| المصدر: | Future Oncology. 18:35-45 |
| بيانات النشر: | Future Medicine Ltd, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Male, Oncology, Radium-223, Cancer Research, medicine.medical_specialty, Abiraterone Acetate, Bone Neoplasms, Prostate cancer, chemistry.chemical_compound, Internal medicine, Nitriles, Phenylthiohydantoin, Humans, Medicine, Enzalutamide, Aged, Retrospective Studies, Aged, 80 and over, Taxane, business.industry, Real world outcomes, Abiraterone acetate, General Medicine, Middle Aged, medicine.disease, Prostatic Neoplasms, Castration-Resistant, chemistry, Benzamides, Cohort, Prednisone, Hormonal therapy, business, Radium, medicine.drug |
| الوصف: | Lay abstract Patients with metastatic castration-resistant prostate cancer are often first treated with novel hormonal therapy (NHT) using abiraterone or enzalutamide. To aid decisions about what treatment to use next, we reviewed information about patients who were treated with an alternative NHT (226 patients) or the nuclear medicine radium-223 (120 patients) after the first NHT. Most patients given radium-223 had cancer that had spread to their bones only, whereas many patients given an alternative NHT had cancer in their bones and other parts of their body. Around one in four patients given radium-223 and one in five given an alternative NHT had symptoms related to their bone metastases after starting treatment. Five in every ten patients given radium-223 received further therapy, including chemotherapy in 50% of these patients, while four in every ten patients given an alternative NHT received further therapy, including chemotherapy in 75%. On average, patients lived for almost a year after starting radium-223 or an alternative NHT. |
| تدمد: | 1744-8301 1479-6694 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::372155e1258fff7d2e39ba8421d02e7cTest https://doi.org/10.2217/fon-2021-0886Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....372155e1258fff7d2e39ba8421d02e7c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17448301 14796694 |
|---|